Pfizer
Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial
Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination
BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn
BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements
Pfizer Transfers Global Creative Duties to Publicis in Strategic Marketing Shift
Pfizer, Publicis, global creative duties, marketing strategy, pharmaceutical industry
Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval
Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen
Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics
Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D
Angela Hwang Joins Flagship Pioneering as CEO-Partner and CEO of Metaphore Biotechnologies
Angela Hwang, Flagship Pioneering, Metaphore Biotechnologies, Pfizer, Biotechnology, Leadership Appointment
Pfizer Weighs Sale of Hospital Drugs Unit Amid Activist Pressure
Pfizer, hospital drugs unit, sale, activist investor, Starboard Value, Goldman Sachs
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying